Target GenDx
Advisory sell side William Blair | Investment Banking
Buyer Eurobio Scientific
Advisory buy side Rothschild & Co. | M&A Advisory
Deloitte | Financial and Fiscal Advisory
Jones Day | Legal Advisory
NextStage AM | Investment Banking
Date announced 2022-08-21
Data Room provider Virtual Vaults

The Dutch biotech company Genome Diagnostics BV (GenDx) is set to be acquired by Eurobio Scientific. They will pay €135 million in cash to the shareholders of DenDx, which is based at the Utrecht Technology Park. Among other things, GenDx develops software to find suitable stem cell transplant donors. Eurobio Scientific is a leading French group for ‘in vitro’ medical diagnostics and life sciences. By acquiring 100% of GenDx's capital and voting rights, the acquisition will strengthen Eurobio Scientific's geographic footprint, primarily in Europe and the United States.

The acquisition will also allow Eurobio Scientific to complete its commercial portfolio with a 100% proprietary portfolio, one of the most effective in the diagnostics field for assessing compatibility between donor and recipient in the context of organ and bone marrow transplantation. This will consolidate the group's position in its specialty area of transplantation diagnostics.

The final completion of the acquisition is still subject to the legal finalisation of an agreement with the bank, which will contain the usual covenants for such transactions. The respective committees having already given their agreements. Scheduled for mid-October.

Source Merger Market
Source fd.